Acute hypokalaemic periodic paralysis is a neuromuscular disorder characterised by recurrent episodes of muscle weakness or paralysis triggered by a sudden drop in blood potassium levels. Attacks can last anywhere from a few hours to several days before resolving spontaneously. However, repeated episodes over many years can lead to permanent muscle damage.

The word “periodic” captures the most defining feature of this condition: the weakness does not persist continuously but arrives in discrete attacks, between which the patient returns fully or largely to normal.

Why Is Potassium so Critical?

Potassium is an ion that is essential for muscle cells to conduct electrical impulses. When blood potassium falls below the normal range — 3.5–5.0 mEq/L — the electrical potential of the muscle cell membrane is disrupted, and the muscles become unable to respond to stimulation. The result is a flaccid muscle weakness. The faster and deeper the drop in potassium, the more severe the clinical picture.

What Are the Types of the Disease?

Hypokalaemic periodic paralysis is examined under two main headings.

Primary (Hereditary) Form

This form is caused by a genetic ion channel mutation. The most common type arises from a mutation in the CACNA1S gene, which encodes a calcium channel, and is known as Type 1. A mutation in the SCN4A gene, which encodes a sodium channel, gives rise to Type 2. Both types follow an autosomal dominant inheritance pattern — meaning the condition can be passed from an affected parent to a child. It presents more frequently and more severely in males. The first attack typically occurs during adolescence.

Secondary (Acquired) Form

This form develops when an underlying disease or an external factor leads to potassium loss or a shift of potassium into cells. The most significant secondary cause is thyrotoxic periodic paralysis — a form associated with hyperthyroidism that is notably more common in males of East Asian descent. Other secondary causes include excessive vomiting, diarrhoea, diuretic use, primary hyperaldosteronism, and renal tubular acidosis.

What Triggers the Attacks?

Attacks are typically precipitated by specific triggers. Carbohydrate-rich meals stimulate insulin secretion, which drives potassium into cells and lowers blood potassium. The rest period following vigorous exercise is a classic trigger. Stress, cold exposure, alcohol consumption, and heavy carbohydrate loading are other well-recognised precipitants. Attacks most commonly occur in the early hours of the morning, upon waking from sleep.

What Is the Clinical Picture?

Weakness typically begins in the legs and is most pronounced in the proximal muscles — those closest to the trunk. In severe cases it can spread to the arms, trunk, and respiratory muscles. The facial and ocular muscles are generally spared. Deep tendon reflexes diminish or disappear during an attack. Consciousness is always preserved. Cardiac arrhythmias can accompany an attack — this is the most important indicator that hypokalaemic periodic paralysis can pose a life-threatening risk.

How Is It Diagnosed?

Detection of a low potassium level in blood drawn during an attack provides the most important contribution to diagnosis. However, diagnosis is not always straightforward; potassium levels may be entirely normal between attacks. Thyroid function tests are mandatory to exclude a secondary form. Genetic analysis is definitive in diagnosing the hereditary form. EMG and exercise testing support the diagnosis. A family history of similar episodes is an important diagnostic clue.

Treatment

In the management of an acute attack, oral or intravenous potassium replacement is administered. When the intravenous route is used, careful dose calculation is essential — administering potassium too rapidly increases cardiac risk. During an attack, carbohydrate-rich foods and glucose-containing fluids should be avoided, as these accelerate the shift of potassium into cells.

For long-term prophylaxis, dietary restriction of carbohydrates and salt, regular mild exercise, and avoidance of known triggers are recommended. Acetazolamide, a carbonic anhydrase inhibitor, is frequently used to prevent attacks in the primary form. In thyrotoxic periodic paralysis, successful treatment of the underlying hyperthyroidism typically leads to complete resolution of attacks.

Prognosis

With early diagnosis and appropriate treatment, attacks can largely be brought under control. However, patients who experience repeated severe attacks over many years may develop permanent proximal muscle weakness. Timely diagnosis and sustained follow-up are therefore of critical importance in preventing long-term disability.